

09926028 09.16.01
518 Rec'd PCT/PTO 16 AUG 2001

FORM PTO-1390 (Modified) (REV 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 212833US0PCT	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 09/926028)	
INTERNATIONAL APPLICATION NO. PCT/JP00/00902		INTERNATIONAL FILING DATE 17 FEBRUARY 2000		PRIORITY DATE CLAIMED 17 FEBRUARY 1999	
TITLE OF INVENTION METHOD FOR ANALYZING EXPRESSION FREQUENCIES OF GENES					
APPLICANT(S) FOR DO/EO/US Takami MAEKAWA, et al.					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below. 4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). 11. <input type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409). 12. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210). 					
Items 13 to 20 below concern document(s) or information included:					
<ol style="list-style-type: none"> 13. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15. <input type="checkbox"/> A FIRST preliminary amendment. 16. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 17. <input type="checkbox"/> A substitute specification. 18. <input type="checkbox"/> A change of power of attorney and/or address letter. 19. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825. 20. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 21. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 22. <input type="checkbox"/> Certificate of Mailing by Express Mail 23. <input checked="" type="checkbox"/> Other items or information: 					
Request for Consideration of Documents in International Search Report Notice of Priority / PCT/IB/304 / PCT/IB/308 Drawings (5 sheets)					

518 Rec'd PCT/PTO 16 AUG 2001


U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.492 (a)) 09/926028	INTERNATIONAL APPLICATION NO. PCT/JP00/00902	ATTORNEY'S DOCKET NUMBER 212833US0PCT
---	--	---


24. The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :				CALCULATIONS PTO USE ONLY	
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000.00					
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00					
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00					
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00					
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$860.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than _____ <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				\$0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	9 - 20 =	0	x \$18.00	\$0.00	
Independent claims	1 - 3 =	0	x \$80.00	\$0.00	
Multiple Dependent Claims (check if applicable). <input checked="" type="checkbox"/>				\$270.00	
TOTAL OF ABOVE CALCULATIONS =				\$1,130.00	
<input type="checkbox"/> Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2.				\$0.00	
SUBTOTAL =				\$1,130.00	
Processing fee of \$130.00 for furnishing the English translation later than _____ <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				\$0.00	
TOTAL NATIONAL FEE =				\$1,130.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL FEES ENCLOSED =				\$1,130.00	
				Amount to be: refunded	\$
				charged	\$

- a. ☒ A check in the amount of \$1,130.00 to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 15-0030 A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:


22850
 (703) 413-3000


WILLIAM E. BEAUMONT
 SIGNATURE REGISTRATION NUMBER 30,996
 Norman F. Oblon
 NAME
 24,618
 REGISTRATION NUMBER
 August 16, 2001
 DATE

09926128 .. 11/16/01
Rec'd PCT/PTO 22 MAY 2002

#5/a

Docket No.: 212833US0PCT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF: :

Takami MAEKAWA, et al. :

SERIAL NO: 09/926,028 : ATTN: BOX SEQUENCE

FILED: AUGUST 16, 2001 :

FOR: METHOD FOR ANALYZING EXPRESSION FREQUENCIES OF GENES

PRELIMINARY AMENDMENT AND STATEMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

In response to the Office Communication mailed March 22, 2002, please amend the above-identified application as follows:

IN THE SPECIFICATION

Please delete the original Sequence Listing.

Please replace the paragraph beginning on page 14, line 13, with the following text:

Fig. 1 shows an exemplary structure of plasmid DNA for producing a vector primer (MAGE/pUC19). The structure of the MAGE/pUC19 is shown having a multiple cloning sequence of GATTCGTGCAGATCTCACACTGCAGAGATCCAACAGCATGGAAGCTT (plus strand; SEQ ID NO: 1) and the corresponding minus strand having a sequence (5' to 3') of AAGCTTCCATGCTGTTGGATCTCTGCAGTGTGAGATCTGCACGAATTC (SEQ ID NO: 17). In this, and subsequent, figure(s), the term "plus strand" represents the top sequence, which is shown in the figure in 5' to 3' orientation, and the term "minus strand" represents the bottom sequence, which is shown in the figure in 3' to 5' orientation.

Please replace the paragraph beginning on page 14, line 22, with the following text:

At page 38 (Abstract), after the last line, beginning on a new page, please insert the attached substitute Sequence Listing.

Claims 1-8 are pending in the present application.

Applicants submit that a surcharge for filing the application in the absence of an Oath or Declaration is not required. Applicants submit herewith a copy of the Declaration as

originally filed, along with a copy of the date-stamped filing receipt evidencing timely filing thereof. In the event that the Office determines that a surcharge is required, the Commissioner is hereby authorized to charge any additional fees to Deposit Account No. 15-0030.

Respectfully submitted,

[Handwritten signature]

Vincent K. Shier
Registration No. 50,552



22850

Phone #: (703) 413-3000
Fax #: (703) 413-2220
NFO/VKS

I:\atty\VKS\212833US0PCT-seq resp.wpd

Docket No.: 212833US0PCT

Serial No.: 09/926,028

MARKED-UP COPY

IN THE SPECIFICATION

Please delete the original Sequence Listing.

Please replace the paragraph beginning on page 14, line 13, with the following text:

Fig. 1 shows an exemplary structure of plasmid DNA for producing a vector primer (MAGE/pUC19). The structure of the MAGE/pUC19 is shown having a multiple cloning sequence of GATTCGTGCAGATCTCACACTGCAGAGATCCAACAGCATGGAAGCTT (plus strand; SEQ ID NO: 1) and the corresponding minus strand having a sequence (5' to 3') of AAGCTTCCATGCTGTTGGATCTCTGCAGTGTGAGATCTGCACGAATTC (SEQ ID NO: 17). In this, and subsequent, figure(s), the term “plus strand” represents the top sequence, which is shown in the figure in 5' to 3' orientation, and the term “minus strand” represents the bottom sequence, which is shown in the figure in 3' to 5' orientation.

Please replace the paragraph beginning on page 14, line 16, with the following text:

Fig. 2 shows an exemplary structure of a vector primer and a construction process therefor. PstI and BstXI cleavage results in the following DNA fragments (all listed 5' to 3') shown in Fig. 2B: GAATTCGTGCAGATCTCACACTGCA (SEQ ID NO: 18) GAGATCCAACAGC (SEQ ID NO: 19) ATGGAAGCTT (SEQ ID NO: 20) GTGTGAGATCTGCACGAATTC (SEQ ID NO: 21) TTGGATCTCTGCA (SEQ ID NO: 22) AAGCTTCCATGCTG (SEQ ID NO: 23). In Fig. 2C, a partially double-stranded DNA having a single-stranded poly(T) sequence is introduced having the following DNA sequences (all listed 5' to 3'): CGGAGTTTAAACGGATTGGAGCCAGC (SEQ ID NO: 24)

ID NO: 32) and

AAGCTTCCATGCTGGCTCCAATCCGTTTAAACTCCGTTTTTTTTTTTTTTTTNNNNN

NNNNNNNNNNNNNNNNNNNNNNNNNNNNNGATCTGCACGAATTC (plus strand; SEQ ID

NO: 33). Following BsgI and PmeI treatment, Fig. 4J shows the following DNA fragments

(all listed 5' to 3'): GAATTCGTGCAGATCNNNNNNNNNNNNNN (SEQ ID NO: 34)

NNNNNNNNNNNNNNNNNNNNNAAAAAAAAAAAAAAAAACGGAGTTT (SEQ ID NO: 35)

AAACGGATTGGAGCCAGCATGGAAGCTT (SEQ ID NO: 36)

NNNNNNNNNNNGATCTGCACGAATTC (SEQ ID NO: 37)

AAACTCCGTTTTTTTTTTTTTTTTNNNNNNNNNNNNNNNNNNNNNNNNNN (SEQ ID NO: 38)

AAGCTTCCATGCTGGCTCCAATCCGTTT (SEQ ID NO: 39). Following 1) blunting of

ends and 2) ligation and cyclization Fig. 4K provides the following exemplary sequence (5' to 3'):

GAATTCGTGCAGATCNNNNNNNNNNNNNAAACGGATTGGAGCCAGCATGGAAGCTT

(plus strand; SEQ ID NO: 40) and

AAGCTTCCATGCTGGCTCCAATCCGTTTNNNNNNNNNNNNNGATCTGCACGAATTC

(bottom strand; SEQ ID NO: 41). In Fig. 4L, a exemplary PCR amplification product is

provided with the following sequence (5' to 3'): GATCNNNNNNNNNNNNNAAACGGATC

(plus strand; SEQ ID NO: 42) and GATCCGTTTNNNNNNNNNNNNNGATC (minus strand;

SEQ ID NO: 43).

Please replace the paragraph beginning on page 14, line 22, with the following text:

Fig. 5 schematically shows the step (e) of the method of the present invention and a step of inserting an amplification product obtained in the step (e) into a cloning vector for sequencing. The small DNA fragment (listed 5' to 3') is GATCNNNNNNNNNNNNNAAACG

(plus strand; SEQ ID NO: 44) and GATCCGTTNNNNNNNNNN (minus strand; SEQ ID NO: 45).

At page 38 (Abstract), after the last line, beginning on a new page, please insert the attached substitute Sequence Listing.



22850

5 / prts

1

Method for analyzing expression frequencies of genes

Technical Field

The present invention relates to a method for analyzing expression frequencies of genes. More precisely, the present invention relates to a method that enables analysis of types and amounts of mRNA expressed from all of genes coding for proteins in a cell even with a small amount of biosample in order to elucidate dynamic change of gene expression.

Background Art

The total number of genes on the genome coding for proteins is expected to be about 100,000 for human. As for yeast, of which total genomic structure have already been elucidated, the number of genes coding for proteins are estimated to be about 5000.

In recent years, public gene databanks have been established mainly in Europe, the United States and Japan. An enormous amount of gene information has been registered at such databanks from all over the world, and further information is newly coming together into the databanks every day. The human genome project is currently being pursued in a worldwide scale aiming at

elucidating the total genes of human genome by the year of 2005, and the gene information obtained in that project is also being registered at the databanks. By inquiring to such databanks about a certain gene sequence, one can know if any gene having the same sequence as, or analogous sequence to the gene sequence has already been registered or not and, if registered, information concerning the sequence including designation and function of the gene, related references and so forth. Such a search is called homology search. There are several kinds of software for performing homology search. However, when a large number of samples must be searched for, BLAST is usually used, of which searching time is short.

Usually, all of genes contained in a cell are not necessarily transcribed into mRNA so as to produce proteins from mRNA, and it is estimated for human that about 15000 genes are expressed in one cell. Thus, in a cell, many kinds of genomic genes are expressed, and a corresponding number of types of messenger RNA (henceforth referred to as "mRNA") are produced. However, types and amounts of expressed genes (also referred to as "genetic expression frequency information" hereinafter) may vary depending on the types and conditions of cells. For example, when a blood stem cell

differentiates into a lymphocyte precursor cell, pre-B cell, B cell, and then activated B cell, each cell shows entirely different gene expression, although there are also genes that are commonly expressed in them.

Measurement of such genetic expression frequency information as described above is called genetic expression profile analysis. Substances responsible for cellular life activities are mainly proteins, and it is important to analyze types and amounts of proteins translated from mRNAs as the genetic expression analysis. However, it is technically difficult under a current situation to obtain profiles for the total proteins. On the other hand, measurement of total types of mRNA has already become possible.

The method reported for the first time as the genetic expression profile analysis method is the Body Map method (Gene, 174, 151-158 (1996)). The outline of the Body Map method is as follows. A poly(T) sequence on a vector is annealed to a poly(A) tail at the 3' end of each mRNA, and a cDNA is synthesized by using the vector poly(T) sequence as a primer. Further, the cDNA is digested with a restriction enzyme *Mbo*I. Since one of *Mbo*I site exists in every 300 base pairs of cDNA in average, the cDNA on the vector is digested into a length of 300 base pairs in

average. At this time, a cDNA fragment nearest the poly(A) tail remains ligated to the vector. The vector having this cDNA fragment is each cyclized and introduced into *Escherichia coli* to prepare a cDNA library. About 1000 clones are arbitrarily selected from the library, and the nucleotide sequence for 300 base pairs in average of each clone is determined. The clones were divided into groups of clones having the same sequence, and type and occurring frequency of each sequence are calculated to obtain genetic expression profile. Homology search (BLAST search) is performed in a databank for each cDNA sequence, and clones containing genes having the same sequence as known genes are given the names of the genes. When the sequence is not registered at the databank, it is considered that no gene corresponding to the sequence exists.

In order to perform homology search by the BLAST search, information for at least 11 base pairs is required. The types of sequences consisting of 10 nucleotides are about 1,000,000, and this number is far beyond the number of gene types of which existence is expected in human, i.e., 100,000. That is, if there is information for 11 base pairs, a gene having the sequence can be identified and thus the genetic expression profile analysis is possible. Therefore, if, aiming at increasing the efficiency of the

genetic expression profile analysis by Body Map which requires much sequencing, cDNA fragments of about 300 base pairs used in Body Map are further made into short fragments of 11 base pairs or more (called "tag"), many of these fragments are ligated and inserted into a vector to prepare a library of ligated tags, about 1000 clones are arbitrarily selected as in Body Map, and DNA sequences of the ligated tags are determined, it is expected that more genetic expression information can be obtained with the same labor compared with Body Map. Each tag represents a gene sequence, and occurring frequency of the tag indicates expression frequency of the gene. Since the length of DNA sequence that can be determined by once of sequencing is usually about 600 base pairs, DNA sequences of about 50 tags at most can be determined by once of sequencing. That is, it becomes possible to perform the genetic expression profile analysis with efficiency about 50 times higher than that of the Body Map method.

As a method for genetic expression profile analysis based on the aforementioned concept, there is the method of serial analysis of gene expression (SAGE, U.S. Patent Nos. 5,695,937 and 5,866,330, European Patent Publication No. 0761822 A). In SAGE, cDNA is produced by using a poly(T) of which 3' end is bonded with biotin as a primer, the cDNA is digested with a restriction

enzyme such as *MboI* (called an "anchoring enzyme") as in Body Map, cDNA fragments containing the 3' end to which biotin is bonded are adsorbed on avidin beads, the beads are divided into two of portions, and two kinds of linkers (A or B) are each ligated to the cDNA fragments (about 13 bp) adsorbed on either of the two portions of the beads. Each linker contains a site for a Class II restriction enzyme such as *BsmFI* (called a "tagging enzyme"). Each cDNA fragment is excised from the beads with the tagging enzyme, the excised end is blunt-ended, and the tags ligated to the linker A and the linker B are connected. The product of the connection is called a "ditag". The ditag is amplified by PCR using primers that recognize the linker A and the linker B. A large number of amplified ditags are ligated, inserted into a vector, and sequenced. About 50 tag sequences can be obtained by once of sequencing. By calculation based on this tag sequence information, genetic expression frequencies are provided.

Further, as other methods for analyzing expression frequencies of genes, there are the gene chip method and the gene microarray method. In both of the methods, there are used gene fragments adhered in array to a suitable plate (usually slide glass) at an extremely high density (about 10 fragments/mm² or more). The

gene fragments on this chip are hybridized with fluorescence-labeled mRNAs to determine types and amounts of mRNAs.

As described above, several methods have been developed for analyzing expression frequencies of genes, and fair results have been obtained. Currently, the SAGE method is the most effective means for measuring expression frequencies of the total genes of all eukaryotic organisms. However, when this method was actually practiced, it encountered many problems, and the SAGE method could not be reproduced in most of research facilities. That is, the techniques required for the SAGE method are complicated and they can be performed only by specially trained persons. Further, about 1 μ g of mRNA is required for the measurement, and therefore it is substantially impossible to perform the measurement with a sample that can be obtained in a small amount, for example, a clinical biopsy material, or to measure difference of genetic expression in micro tissue portions. Furthermore, the method theoretically causes considerable measurement errors.

In the SAGE method, it is extremely important to accurately determine a sequence of the tag. This is because the tag is short (about 13 bp) and therefore, if even only one of nucleotides is erroneously determined, it may be

determined to be a different sequence even though it is the same sequence, or a different sequence may be determined to be the same sequence. However, such an erroneous determination is likely to occur in the SAGE method. This is because, in the SAGE method, two tags are connected to form a ditag and the border between the tags becomes indefinite. The tag is a short gene fragment excised by a restriction enzyme such as *BsmFI* and *FokI*. However, cleavage sites of these enzymes are not always stable, and the lengths of the excised tags are diversified. Thus, if the tags are connected to form a ditag in the state that tags of different lengths are intermingled, it becomes indefinite from which tag nucleotides at the ligation site of the tags have been derived. As a result, it becomes impossible to obtain a correct sequence of the tag. Thus, the SAGE method suffers from a theoretically inevitable drawback. Furthermore, the SAGE method involves an operation of collecting DNA using avidin and biotin beads. However, it is in fact extremely difficult to collect DNA by using avidin and biotin beads without inviting contamination, and it is extremely difficult to obtain correct data by operating according to the protocol as it is. Moreover, the SAGE method requires a large amount of mRNA in order to obtain data. Therefore, in a

case of a sample of which amount is limited, for example, clinical samples, a sufficient amount of mRNA cannot be obtained and thus the SAGE method cannot be performed.

Furthermore, in the gene chip method and the gene microarray method, the measurement can be performed only for a gene of which structure is known, unlike the Body Map method or the SAGE method. Therefore, under the current situation, expression frequencies of total genes of all organisms cannot be measured.

Currently, the SAGE method is the most effective means for measuring expression frequencies of the total genes of all eukaryotic organisms. However, when this method was actually practiced, it encountered many problems, and the SAGE method could not be reproduced in most of research facilities. The drawbacks of the SAGE method are as follows: (1) the techniques required for the method are complicated and they can be performed only by specially trained persons; (2) about 1 μ g of mRNA is required for the measurement, and therefore it is substantially impossible to perform the measurement with a sample that can be obtained in a small amount, for example, a clinical biopsy material, and it is similarly impossible to measure difference of genetic expression in micro tissue portions; and (3) the method theoretically

causes considerable measurement errors because a ditag is measured.

Disclosure of the Invention

The present invention was accomplished in view of the aforementioned current situation, and an object thereof is to provide a method that can be easily performed by ordinary researchers and enables accurate genetic expression frequency analysis with a micro amount of a specimen.

The inventors of the present invention assiduously studied in order to achieve the aforementioned object. As a result, they found that expression frequencies of genes could be efficiently analyzed with high precision by synthesizing each cDNA from each mRNA using a vector primer having a poly(T) sequence, converting each cDNA sequence to a tag on the vector, forming a concatemer by ligating the obtained tags via a sequence that enables recognition of ends of the tags, and analyzing a nucleotide sequence of the concatemer, and thus accomplished the method of the present invention designated as "MAGE (Micro-analysis of Gene Expression)".

That is, the present invention provides the followings.

(1) A method for analyzing expression frequencies of genes, which comprises the

following steps:

- (a) a step of forming a vector primer to which each cDNA is ligated, by annealing the vector primer with each mRNA derived from a cell of which expression frequencies of genes is to be analyzed, and synthesizing the cDNA, said vector primer comprising a linear plasmid vector having a single-stranded poly(T) sequence at one 3' end, a recognition sequence for a first restriction enzyme in an inner position from the poly(T) sequence, a recognition sequence for a second restriction enzyme near the other end, and a recognition sequence for a type IIS restriction enzyme in an inner position from the recognition sequence for the second restriction enzyme,
- (b) a step of digesting the vector primer to which the cDNA is ligated, with the second restriction enzyme and a third restriction enzyme that does not digest the vector primer and forms a digested end of the same shape as a digested end obtained with the second restriction enzyme, to excise an upstream region of the cDNA, and cyclizing the vector primer,
- (c) a step of digesting the cyclized vector primer with the first restriction enzyme and the type IIS restriction enzyme to excise a downstream region of the cDNA so that a tag consisting of a part of the cDNA is left, and cyclizing the vector primer again,

nucleotides.

(5) The method according to any one of (1) to (4), wherein the vector primer has a recognition sequence for a fourth restriction enzyme of which digestion point is in the same position as or an inner position from the digestion point of the recognition sequence for the second restriction enzyme, which is not excised from the vector primer by the digestion with the type IIS restriction enzyme;

the primer for the downstream side of the tag among the primers used in the step (d) has a recognition sequence for a fifth restriction enzyme that forms an end of the same shape as the end digested with the fourth restriction enzyme; and

the concatemer is formed after the amplified primers are digested with the fourth restriction enzyme and the fifth restriction enzyme.

(6) The method according to (5), wherein the vector primer has a nucleotide sequence different from the recognition sequence for the fifth restriction enzyme by one nucleotide in an inner position from the recognition sequence for the first restriction enzyme, and the nucleotide sequence different by one nucleotide is converted to the recognition sequence for the fifth restriction enzyme by PCR using the primer for the downstream side of the tag.

(7) The method according to (6), wherein the third, fourth and fifth restriction enzymes are identical to one another.

(8) The method according to any one of (1) to (7), wherein the vector primer is formed by ligating a linear plasmid obtained by digesting a plasmid having a multicloning site at two sites in the multicloning site, and a partially double-stranded DNA having an end of the same shape as one end of the linear plasmid and a single-stranded poly(T) sequence.

Brief Explanation of the Drawings

Fig. 1 shows an exemplary structure of plasmid DNA for producing a vector primer (MAGE/pUC19).

Fig. 2 shows an exemplary structure of a vector primer and a construction process therefor.

Fig. 3 schematically shows the steps (a) and (b) of the method of the present invention.

Fig. 4 schematically shows the steps (c) and (d) of the method of the present invention.

Fig. 5 schematically shows the step (e) of the method of the present invention and a step of inserting an amplification product obtained in the step (e) into a cloning vector for sequencing.

Best Mode for Carrying out the Invention

The method of the present invention

comprises the aforementioned steps (a) to (f). Hereafter, each step will be explained.

<1> Step (a)

In the first step, a vector primer comprising a linear plasmid vector having a single-stranded poly(T) sequence at one 3' end, a recognition sequence for a first restriction enzyme in an inner position from the poly(T) sequence, a recognition sequence for a second restriction enzyme near the other end, and a recognition sequence for a type IIS restriction enzyme in an inner position from the recognition sequence for the second restriction enzyme is used (also referred to as a "the vector primer for reverse transcription" hereinafter). The type IIS restriction enzyme means a restriction enzyme that cleaves a specific position remote from a sequence recognized by the restriction enzyme.

An exemplary structure of the vector primer is shown in Fig. 2, D. This vector primer can be prepared by, for example, ligating a linear plasmid obtained by digesting a plasmid having a multicloning site at two sites in the multicloning site, and a partially double-stranded DNA having an end of the same shape as one end of the linear plasmid and a single-stranded poly(T) sequence. The structure of MAGE/pUC19 is shown in Fig. 1 as an example of the plasmid having a multicloning site. This

primer comprises pUC19, which is a known cloning vector, as a basic structure, and a sequence containing various restriction enzyme recognition sites (referred to as "Z fragment", sequence is shown in SEQ ID NO: 1) is inserted between the *EcoRI* and *HindIII* restriction enzyme sites of the multicloning site thereof.

In the following specific example, explanation will be made for an example that utilizes MAGE/pUC19 prepared by using an *Escherichia coli* host having Dam methylation system, for example, JM109 strain etc. However, it is not essential for the present invention. Further, the vector used as the basic structure is not limited to pUC19, and various other vectors such as pUC18, pBR322, pHSG299, pHSG298, pHSG399, pHSG398, RSF1010, pMW119, pMW118, pMW219 and pMW218 can be used. In addition, the host of the vector is not particularly limited, so long as it is one for which ordinary genetic recombination techniques such as transformation and recovery of vectors from the host can be used. However, *Escherichia coli* is usually used.

An example utilizing MAGE/pUC19 as the plasmid having a multicloning site will be explained hereafter. However, the present invention is not limited to this example.

First, MAGE/pUC19 vector (Fig. 2, A) is digested with restriction enzymes *BstXI* and *PstI*,

and the excised small fragment is removed (Fig. 2, B). Then, a partially double-stranded DNA having a single-stranded poly(T) sequence (poly(T) adaptor shown in Fig. 2, C) is ligated to the *Bst*XI-digested end. This provides a vector primer (or a vector primer for reverse transcription) in which the single-stranded poly(T) protruding from one end of the MAGE/pUC19 vector (Fig. 2, D). In this vector primer, the first restriction enzyme is *Pme*I, the second restriction enzyme is *Bgl*II, and the type IIS restriction enzyme is *Bsg*I.

The recognition sequence for the second restriction enzyme *Bgl*II contains an overlapping *Mbo*I recognition sequence, and therefore if the *Bgl*II end is ligated to the *Mbo*I end, it can be digested with *Mbo*I. Further, in this example, the vector primer is designed to contain a nucleotide sequence (Δ *Mbo*I of Fig. 3, E) that is different from the fourth restriction enzyme (*Mbo*I) recognition sequence by one nucleotide in a further inner position from the first restriction enzyme (*Pme*I) recognition sequence. This Δ *Mbo*I and the first restriction enzyme recognition sequence of the vector primer are derived from the poly(T) adaptor.

The first restriction enzyme and the second restriction enzyme are not particularly limited, so long as they digest the vector primer at one position. Further, the type IIS restriction

enzyme and its recognition sequence-existing position are not particularly restricted, so long as it does not excise the fourth restriction enzyme site from the vector primer, and it digests the upstream region of the cDNA so that a part of the cDNA is left on the vector primer. Specifically, it may be, for example, *BsmFI* etc., in addition to the aforementioned *BsgI*.

Further, the length of the poly(T) sequence may be a length that enables annealing with the poly(A) sequence of mRNA, and it is usually about 10-50 nucleotides.

Such a vector primer as mentioned above and mRNA derived from a cell for which expression frequencies of genes are to be analyzed are annealed. When a reverse transcription reaction is performed in that state, the poly(T) serves as a primer and cDNA synthesis is initiated (Fig. 3, E). Then, the second strand can be synthesized by using the synthesized first strand of cDNA as a template to synthesize a double-stranded cDNA (Fig. 3, F). While a large number of vector cDNA-ligated primer molecules (cDNA-MAGE/pUC19) can be produced from a large number of mRNA molecules, Fig. 3, F represents one of typical example thereof.

The mRNA is extracted from a cell for which expression frequencies of genes are to be analyzed. Any cell can be used as the cell for

which expression frequencies are to be analyzed without any particular limitation, so long as it is a cell in which 3' end of mRNA has the poly(A) structure, and it may be a tissue cell of an animal or a plant, a cell of a microorganism such as yeast. Further, mRNA of a prokaryote does not have the poly(A) structure at the 3' end and therefore it cannot be annealed as it is to the poly(T) of the vector primer. However, by enzymatically adding a poly(A) structure to the mRNA, the method of the present invention can be performed in a manner similar to that for mRNA of an eukaryotic organism.

Operations such as preparation of mRNA, cDNA synthesis, synthesis of oligonucleotide, reaction with a restriction enzyme, ligation reaction, polymerase chain reaction (PCR), and transformation can be performed in the same manner as methods for preparing mRNA used for usual cDNA cloning (see, for example, Sambrook J., Fritsch, E.F., and Maniatis, T., "Molecular Cloning A Laboratory Manual, Second Edition", Cold Spring Harbor Laboratory Press (1989) etc.).

<2> Step (b)

Then, the vector primer to which cDNA is ligated, obtained as described above, is digested with the second restriction enzyme and a third restriction enzyme that does not digest the

vector primer and forms a digested end of the same shape as a digested end obtained with the second restriction enzyme, to excise an upstream region of the cDNA, and the vector primer is cyclized. The cyclized vector primer can be amplified by introducing it into a suitable host, culturing the obtained transformant, and collecting a plasmid. As will be similarly applied to cyclized vector primers used in the subsequent steps, when the restriction enzyme site for cleaving the obtained vector primer cannot be digested due to Dam methylation, a host that does not have the modification system is used.

As the third restriction enzyme, an enzyme recognizing four nucleotides is preferred. If an enzyme recognizing six nucleotides is used, such a restriction enzyme site may not exist in the cDNA sequence. Further, if the sequence of cDNA left on the vector primer is long, the tag obtained by the subsequent procedures will become far from the poly(A) sequence of mRNA. In such a case, since the expression information of genes in a database (EST: expressed sequence tag) is usually for parts of the 3' end side of mRNA, the target sequence may not be retrieved even if tag sequences are searched. Examples of restriction enzyme suitable for the present invention, which recognize four nucleotides, include *Mbo*I, *Tai*I

and so forth.

Hereafter, an example utilizing *Mbo*I as the third restriction enzyme will be explained. First, the cDNA-ligated vector primer (cDNA-MAGE/pUC19) is digested with restriction enzymes *Bgl*II and *Mbo*I (Fig. 3, G). Since MAGE/pUC19 have been Dam-methylated at this time, it is not digested with *Mbo*I, and only the *Mbo*I site newly synthesized in the cDNA by the reverse transcription is digested. Fig. 3, G shows a temporary example where the cDNA contains three of *Mbo*I sites. As for the cDNA, a downstream region from the poly(A) tail to the first *Mbo*I site toward the upstream region remains ligated to the MAGE/pUC19 vector primer, and the other portion, i.e., the upstream region of the cDNA is excised and removed by the *Mbo*I digestion. As for MAGE/pUC19, it is digested with *Bgl*II at only one position. The end portions digested with *Mbo*I and *Bgl*II are in the same shape, and they can be ligated by a ligation reaction. Therefore, the cDNA-MAGE/pUC19 is cyclized by a self-ligation reaction via these ends (Fig. 3, H).

<3> Step (c)

The vector primer cyclized in the step (b) is digested with the first restriction enzyme and the type IIS restriction enzyme to excise the downstream region of the cDNA, so that a tag

consisting of a part of the cDNA is left, and the vector primer is cyclized again.

Specifically, the cyclized cDNA-MAGE/pUC19 is digested with restriction enzymes *BsgI* and *PmeI* (Fig. 4, I). After digestion with these restriction enzymes, only about 13 nucleotides farthest from the poly(A) tail of the 3' end portion of the cDNA remain on the vector primer. This sequence of cDNA consisting of about 13 nucleotides is called tag (shown in Fig. 4, J as "tag").

Since the strand of 5' end protrudes by 2 bp at the end digested with *BsgI*, it is blunt-ended by T4 DNA polymerase treatment, for example. Further, other end digested with *PmeI* is a blunt end. Therefore, these ends can be ligated (Fig. 4, J). Thus, if the vector primer is cyclized by a self-ligation reaction, a vector primer having a structure comprising MAGE/pUC19 to which a short tag is ligated, in which the part of cDNA other than the tag is excised, is obtained (Fig. 4, J and K).

<4> Step (d)

Then, PCR is performed by using the vector primer cyclized in the step (c) as a template, and oligonucleotides having nucleotide sequences corresponding to respective flanking regions of the both sides of the tag in the vector primer as

primers to amplify the tag.

Specifically, PCR is performed by using the vector primer containing the tag as a template, and primers corresponding to the sequences of the vector segments of the both sides of the tag (for example, those of SEQ ID NOS: 2 and 3) (Fig. 4, K). As a result, a DNA fragment containing the tag at the center is amplified (in this case, 110 bp including the sequences of primers and the tag) (Fig. 4, L).

<5> Step (e)

The aforementioned PCR amplification products are ligated to form a concatemer of the tags. At this time, if a recognition sequence for a fifth restriction enzyme that produces an end of the same shape as the end obtained by digestion with the fourth restriction enzyme is introduced into the primer for the downstream region of the tag among the primers used in the step of (d), and the amplified primer is digested with the fourth restriction enzyme and the fifth restriction enzyme, the concatemer can be formed efficiently. The type of the fifth restriction enzyme is not particularly limited. However, if the same restriction enzyme as the fourth restriction enzyme is used, the procedure will become simple. Further, the same restriction enzyme as the third restriction enzyme may be

used as the fourth restriction enzyme. Furthermore, the third, fourth and fifth restriction enzymes may be the same enzyme. However, if the same enzyme is used as the fifth restriction enzyme and fourth restriction enzyme, the total sequence of the cDNA will be excised from the vector primer in the step (b). Therefore, in order to prevent this, it is necessary to introduce a nucleotide sequence different from the recognition sequence for the fifth restriction enzyme by one nucleotide at a position in a further inner position from the first restriction enzyme recognition sequence of the vector primer, and perform PCR by using a primer having a recognition sequence for the fifth restriction enzyme for the downstream side of the tag so that the nucleotide sequence different by one nucleotide is replaced with the recognition sequence for the fifth restriction enzyme. Further, when the same enzyme is used as the third restriction enzyme and fourth restriction enzyme, the recognition site of the vector primer for the fourth restriction enzyme must be made to be not digested by methylation. In this case, before digestion with the fourth restriction enzyme, the vector primer cyclized in the step (c) is introduced into the host not having the modification system for demodification.

If the ligation reaction of the tags is

performed in the presence of an adaptor having one end of the same shape as an end of the tag to arrange the adaptor at each end of the concatemer, and PCR is performed by using an oligonucleotide having a sequence corresponding to the sequence of the adaptor as a primer, the concatemer can be amplified. If the adaptor is used in a smaller amount compared with the tag, or an adaptor having one end of a shape different from that of the tag, the adaptor can be arranged at each end of a concatemer consisting of a large number of tags. In this way, even a micro amount of concatemer can be cloned, and as a result, analysis becomes possible with a micro amount of sample mRNA.

The molar ratio of the tags and the adaptor is usually tag:adaptor = 1:1 to 1:0.01, preferably 1:0.2 to 1:0.05. If the adaptor is used in this range, the concatemer composed of about 2 to 50 ligated tags may be obtained.

Insertion of the obtained concatemer into a cloning vector for nucleotide sequencing makes the sequencing operation easy.

When MAGE/pUC19 is used, a small fragment containing a tag is obtained by digesting the amplification product of the step (d) with a restriction enzyme *Mbo*I (Fig. 5, M). The tag fragment obtained here is present between known DNA sequences, i.e., GATC and AAACG, and

therefore it can definitely recognize which portion is the tag. Since *Mbo*I sites are exposed at the both ends of this tag sequence, the tags can ligated to each other by a ligation reaction to form a concatemer (Fig. 5, M).

<6> Step (f)

If the nucleotide sequence of the concatemer obtained as described above is determined, since tags derived from many cDNA molecules are contained in it, the expression frequencies of the genes from which the cDNAs originated can be analyzed by investigating types and frequencies of the tags occurring in the nucleotide sequence. Type of the tag can be determined by searching for a database containing information of partial sequences of known mRNAs (EST).

When the concatemer of the tags is amplified, two or more fragments having the same sequence will be formed. However, if a sequence considered to be the same as one previously sequenced appears in the sequence analysis after the cloning, it can be excluded from the analysis to eliminate bad influence of PCR on the genetic expression frequency analysis.

Further, when the same enzyme is used as the fourth and fifth restriction enzymes, since direction of the tags in the concatemer is not fixed, sequences of not only one strand but also

the reverse strand are taken into consideration in the sequence analysis.

As explained above, in the method of the present invention, a ditag is not produced as in the SAGE method, but a tag can be prevented from directly connecting with other tags by putting each tag between known DNA fragments. As a result, the problem that the border between tags becomes indefinite is solved. Further, since a sample can be amplified by performing PCR several times, the analysis can be possible even with a micro amount of mRNA. Furthermore, the use of vector primer enables cDNA synthesis in the state that the cDNA is fused to the vector. Therefore, the analysis can be performed without using avidin and biotin beads.

Example

Thirty five micrograms (35 μ g) of mRNA was extracted from 1 g of C57BL/6 mouse livers by using Fast Track 2.0 kit produced by Invitrogen.

After cDNA was synthesized through reverse transcription by using 0.97 μ g of the obtained mRNA and MAGE/pUC19, genetic expression frequency analysis was performed as follows.

The MAGE/pUC19 vector (Fig. 2, A) was digested with restriction enzymes *Bst*XI and *Pst*I, and the excised small fragment was removed (Fig. 2, B). Then, a partially double-stranded DNA

having a single-stranded poly(T) sequence (poly(T) adaptor shown in Fig. 2, C) was ligated to the *Bst*XI-digested end (Fig. 2, D). In this vector primer, the first restriction enzyme was *Pme*I, the second restriction enzyme was *Bgl*II, and the type IIS restriction enzyme was *Bsg*I (Fig. 3, E).

Zero point two microgram ($0.2\ \mu\text{g}$) of the vector primer and $0.97\ \mu\text{g}$ of the mRNA derived from mouse liver were annealed, and cDNA synthesis was performed. Then a second strand was synthesized by using the synthesized first cDNA as a template (Fig. 3, F). Genetic expression frequency analysis was performed by using the obtained cDNA in an amount of $1/40$ of the obtained amount of cDNA (corresponding to $0.025\ \mu\text{g}$ of mRNA) as a material.

In another experiment, genetic expression frequency analysis could be successfully performed by using $0.05\ \mu\text{g}$ of micro amount mRNA extracted from $4.5\ \text{mg}$ of micro amount clinical sample as an experimental material to synthesize cDNA through reverse transcription and following the same procedures as described below.

Then, the vector primer to which the cDNA was ligated obtained as described above was digested with *Bgl*II and *Mbo*I, which were the second and third restriction enzymes, respectively (Fig. 3, G). Subsequently, the *Mbo*I

end and *Bgl*III end of cDNA-MAGE/pUC19 were ligated by a self-ligation reaction to cyclize the vector primer (Fig. 3, H).

The above cyclized vector primer was digested with *Bsg*I and *Pme*I, and the digested ends were blunt-ended by T4 DNA polymerase treatment. Then, the vector primer was cyclized again (Fig. 4, I to K). PCR was performed by using this cyclized vector primer as a template, oligonucleotides having nucleotide sequences corresponding to the respective flanking regions of the both sides of the tag in the vector primer (SEQ ID NOS: 2 and 3) as primers, and an enzyme AmpliTaq Gold (PE Biosystems) to amplify the tag (Fig. 4, L). The above PCR was performed by repeating a reaction cycle of denaturation (95°C, 0.3 minute), annealing and an extension reaction with the polymerase (72°C, 1.5 minutes) for 65 cycles. As a result, a DNA fragment of 110 bp containing the tag at the center was amplified.

The above PCR amplification product was digested with *Mbo*I to excise the tag, and a ligation reaction was performed with addition of an adaptor obtained by annealing oligonucleotides having the nucleotide sequences shown in SEQ ID NOS: 4 and 5 such that the ratio of tag:adaptor should be 8:1 to form a concatemer of the tags (Fig. 5, M). This concatemer was amplified by PCR using a primer having the nucleotide sequence

shown in SEQ ID NO: 6. For PCR, a reaction cycle of denaturation (95°C, 0.3 minute), annealing (40°C, 3 minutes) and an extension reaction with polymerase (72°C, 1 minute) was repeated for 5 cycles, and then a reaction cycle of denaturation (95°C, 0.3 minute), annealing and an extension reaction (72°C, 1 minute) was repeated for 60 cycles. The amplification product was digested with a restriction enzyme *NotI*, and inserted into the *NotI* site of the cloning vector pKF3 for sequencing, and the nucleotide sequence was determined.

Based on the obtained sequence data (for 11000 tags), the tags were divided into groups of tags having the same sequence, and the order of the groups according to the occurring frequency was determined. The tags ranked first to tenth for the frequency from the highest are shown in Table 1. This result shows that the gene showing the highest expression frequency in the mouse liver tissue was the urinary protein I/II gene. Following that gene, the albumin gene, the urinary protein III gene and the argininosuccinate synthase gene are ranked in the order of the expression frequency from higher one. Thus, even with a micro amount of mRNA sample, the method of the present invention shows high recovery efficiency of cDNA by the use of a vector primer, and enables genetic expression

frequency analysis with high precision since ambiguity of tag sequences can be eliminated.

Table 1

Tag (SEQ ID NO)	Rank for frequency	Number of tag	Designation of gene
TGCATTCCATC (7)	1	2196	Urinary protein I/II
CCTGGTGGAAA (8)	2	1261	Albumin
TGCTCTCCACC (9)	3	485	Urinary protein III
GGGAAGTACGC (10)	4	383	Argininosuccinate synthase
ACCTCGGATGA (11)	5	345	Fibrinogen A α
TTCCAGGCCCG (12)	6	333	Apolipoprotein E
ACCAGTGTCGC (13)	7	310	Mouse EST
TGCATGCCCTG (14)	8	307	Ferritin light chain
CACTACAGCAC (15)	9	300	Mouse EST
CTGCCAAGTTC (16)	10	226	Retinol-binding protein

Industrial Applicability

According to the present invention, expression frequencies of genes can be surely analyzed with good precision in a simple manner.

The method for analyzing genetic expression of the present invention is useful for researches concerning life science, and it is particularly useful for development of methods for treatment or diagnosis of diseases through analysis of difference in genetic expression between specific organs or cells of healthy subjects and subjects with diseases. For example, by analyzing

difference in expression of genes between livers of healthy subject and subject with hepatitis by the method of the present invention, a gene of which expression is specifically increased or decreased in hepatitis can be discovered. By investigating the role in the liver of such a gene, drugs for inhibiting or accelerating the function of the gene can be developed for the purpose of treatment of hepatitis. Moreover, the gene itself, an antisense oligonucleotide designed based on the gene structure, a protein produced by expression of the gene and so forth can also be used for the treatment of hepatitis.

Further, even for a disease of which mechanism for its onset is not elucidated yet, a method of treatment may be developed by using the method of the present invention. Furthermore, if a gene of which expression is changed in a disease-specific manner can be found by the method of the present invention, it becomes possible to develop not only a method of treatment, but also a method of diagnosis of a disease.

Moreover, not only use in the medical field, the method can also be means for identifying useful genes from all of eukaryotic organisms. For example, after yeast strains suitable for the brewing of beer are bred by mutation, change of genetic expression between a parent strain and a

mutant strain can be analyzed by the method of the present invention, so that a gene of which expression is changed by the mutation can be identified. By comprehensively manipulating genes advantageous for the brewing of beer, which are obtained as described above, a better brewers' yeast strain can be created.

Further, by analyzing amino acid-producing bacteria such as *Escherichia coli* and *Corynebacterium* bacteria, for example, more excellent amino acid-producing bacteria can be created.

WHAT IS CLAIMED IS:

1. A method for analyzing expression frequencies of genes, which comprises the following steps:
 - (a) a step of forming a vector primer to which each cDNA is ligated, by annealing the vector primer with each mRNA derived from a cell of which expression frequencies of genes is to be analyzed, and synthesizing the cDNA, said vector primer comprising a linear plasmid vector having a single-stranded poly(T) sequence at one 3' end, a recognition sequence for a first restriction enzyme in an inner position from the poly(T) sequence, a recognition sequence for a second restriction enzyme near the other end, and a recognition sequence for a type IIS restriction enzyme in an inner position from the recognition sequence for the second restriction enzyme,
 - (b) a step of digesting the vector primer to which the cDNA is ligated, with the second restriction enzyme and a third restriction enzyme that does not digest the vector primer and forms a digested end of the same shape as a digested end obtained with the second restriction enzyme, to excise an upstream region of the cDNA, and cyclizing the vector primer,
 - (c) a step of digesting the cyclized vector primer with the first restriction enzyme and the

type IIS restriction enzyme to excise a downstream region of the cDNA so that a tag consisting of a part of the cDNA is left, and cyclizing the vector primer again,

(d) a step of performing polymerase chain reaction (PCR) by using the vector primer as a template and oligonucleotides having nucleotide sequences corresponding to respective flanking regions of the both sides of the tag contained in the vector primer as primers to amplify the tag,

(e) a step of ligating the amplification products to form a concatemer of the tags, and

(f) a step of determining the nucleotide sequence of the concatemer and investigating types and frequencies of tags occurring in the nucleotide sequence.

2. The method according to Claim 1, wherein the ligation reaction in the step (e) is performed in the presence of an adaptor having one end of the same shape as an end of the tag to arrange the adaptor at each end of the concatemer, and the concatemer is amplified by performing PCR using an oligonucleotide having a sequence corresponding to the sequence of the adaptor as a primer.

3. The method according to Claim 1 or 2, wherein, after the step (e), the concatemer is

cloned in a cloning vector for nucleotide sequencing, and then the nucleotide sequence of the concatemer is determined.

4. The method according to any one of Claims 1-3, wherein the recognition sequence for the third restriction enzyme consists of four nucleotides.

5. The method according to any one of Claims 1-4, wherein the vector primer has a recognition sequence for a fourth restriction enzyme of which digestion point is in the same position as or an inner position from the digestion point of the recognition sequence for the second restriction enzyme, which is not excised from the vector primer by the digestion with the type IIS restriction enzyme;

the primer for the downstream side of the tag among the primers used in the step (d) has a recognition sequence for a fifth restriction enzyme that forms an end of the same shape as the end digested with the fourth restriction enzyme; and

the concatemer is formed after the amplified primers are digested with the fourth restriction enzyme and the fifth restriction enzyme.

6. The method according to Claim 5, wherein

the vector primer has a nucleotide sequence different from the recognition sequence for the fifth restriction enzyme by one nucleotide in an inner position from the recognition sequence for the first restriction enzyme, and the nucleotide sequence different by one nucleotide is converted to the recognition sequence for the fifth restriction enzyme by PCR using the primer for the downstream side of the tag.

7. The method according to Claim 6, wherein the third, fourth and fifth restriction enzymes are identical to one another.

8. The method according to any one of Claims 1-7, wherein the vector primer is formed by ligating a linear plasmid obtained by digesting a plasmid having a multicloning site at two sites in the multicloning site, and a partially double-stranded DNA having an end of the same shape as one end of the linear plasmid and a single-stranded poly(T) sequence.

ABSTRACT OF THE DISCLOSURE

In gene expression frequency analysis, a vector primer to which each cDNA is ligated is formed by synthesizing the cDNA from each mRNA using by a vector primer having a poly(T) sequence; each cDNA sequence is converted to a tag on the vector primer; a concatemer is formed by ligating the obtained tags via a sequence that enables recognition of ends of the tags; and the nucleotide sequence of the concatemer is analyzed.

1/5




Fig. 1




Fig. 2




Fig. 3




Fig. 4

09/926028

5/5




Fig. 5

B-583

Declaration, Power Of Attorney and Petition

Page 1 of 3

WE (I) the undersigned inventor(s), hereby declare(s) that:

My residence, post office address and citizenship are as stated below next to my name,

We (I) believe that we are (I am) the original, first, and joint (sole) inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Method for analyzing expression frequencies of genes

the specification of which

☒ is attached hereto.

☐ was filed on _____ as

Application Serial No. _____

and amended on _____

☒ was filed as PCT international application

Number PCT/JP 00/00902

on February 17, 2000,

and was amended under PCT Article 19

on _____ (if applicable).

We (I) hereby state that we (I) have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

We (I) acknowledge the duty to disclose information known to be material to the patentability of this application as defined in Section 1.56 of Title 37 Code of Federal Regulations.

We (I) hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed. Prior Foreign Application(s)

Application No.	Country	Day/Month/Year	Priority Claimed
11-38538	Japan	17/02/1999	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No

We (I) hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

(Application Number)

(Filing Date)

(Application Number)

(Filing Date)

We (I) hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application Serial No.

Filing Date

Status (pending, patented,
abandoned)

Application Serial No.	Filing Date	Status (pending, patented, abandoned)

(25) And we (I) hereby appoint: Norman F. Oblon, Registration Number 24,618; Marvin J. Spivak, Registration Number 24,913; C. Irvin McClelland, Registration Number 21,124; Gregory J. Maier, Registration Number 25,599; Arthur I. Neustadt, Registration Number 24,854; Richard D. Kelly, Registration Number 27,757; James D. Hamilton, Registration Number 28,421; Eckhard H. Kuesters, Registration Number 28,870; Robert T. Pous, Registration Number 29,099; Charles L. Gholz, Registration Number 26,395; Vincent J. Sunderdick, Registration Number 29,004; William E. Beaumont, Registration Number 30,996; Steven B. Kelber, Registration Number 30,073; Robert F. Gnuse, Registration Number 27,295; Jean-Paul Lavalleye, Registration Number 31,451; Timothy R. Schwartz, Registration Number 32,171; Stephen G. Baxter, Registration Number 32,884; Martin M. Zoltick, Registration Number 35,745; Robert W. Hahl, Registration Number 33,893; Richard L. Treanor, Registration Number 36,379; Steven P. Weihrouch, Registration Number 32,829; John T. Goolkasian, Registration Number 26,142; Marc R. Labgold, Registration Number 34,651; William J. Healey, Registration Number 36,160; and Richard L. Chinn, Registration Number 34,305; our (my) attorneys, with full powers of substitution and revocation, to prosecute this application and to transact all business in the Patent Office connected therewith; and we (I) hereby request that all correspondence regarding this application be sent to the firm of OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., whose Post Office Address is: Fourth Floor, 1755 Jefferson Davis Highway, Arlington, Virginia 22202.

We (I) declare that all statements made herein of our (my) own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

1-00 Takami MAEKAWA

NAME OF FIRST SOLE INVENTOR

Residence: Kawasaki-shi, Kanagawa, Japan JPX

Signature of Inventor

Citizen of: Japan

Post Office Address:

c/o Ajinomoto Co., Inc., Central Research
Laboratories, 1, Suzuki-cho, Kawasaki-ku,
Kawasaki-shi, Kanagawa, Japan

August 3, 2001

Date

20 Akira MITSUI

NAME OF SECOND JOINT INVENTOR

Akira Mitsui
Signature of Inventor

August 3, 2001
Date

Residence: Kawasaki-shi, Kanagawa, Japan JPX

Citizen of: Japan

Post Office Address:

c/o Ajinomoto Co., Inc., Pharmaceutical
Research Laboratories, 1-1, Suzuki-cho,
Kawasaki-ku, Kawasaki-shi, Kanagawa, Japan

30 Masayo DATE

NAME OF THIRD JOINT INVENTOR

Masayo Date
Signature of Inventor

August 3, 2001
Date

Residence: Kawasaki-shi, Kanagawa, Japan JPX

Citizen of: Japan

Post Office Address:

c/o Ajinomoto Co., Inc., Central Research
Laboratories, 1-1, Suzuki-cho, Kawasaki-ku,
Kawasaki-shi, Kanagawa, Japan

40 Hisao FUKUDA

NAME OF FOURTH JOINT INVENTOR

Hisao Fukuda
Signature of Inventor

August 3, 2001
Date

Residence: Kawasaki-shi, Kanagawa, Japan JPX

Citizen of: Japan

Post Office Address:

c/o Ajinomoto Co., Inc., Central Research
Laboratories, 1-1, Suzuki-cho, Kawasaki-ku,
Kawasaki-shi, Kanagawa, Japan

50 Yoshiyuki TAKAHARA

NAME OF FIFTH JOINT INVENTOR

Yoshiyuki Takahara
Signature of Inventor

August 3, 2001
Date

Residence: Kawasaki-shi, Kanagawa, Japan JPX

Citizen of: Japan

Post Office Address:

c/o Ajinomoto Co., Inc., Central Research
Laboratories, 1-1, Suzuki-cho, Kawasaki-ku,
Kawasaki-shi, Kanagawa, Japan

1/4

SEQUENCE LISTING

<110> Ajimonoto Co., Inc.

<120> Method for analyzing expression frequencies of genes

<130> B-583AYOP962

<150> JP 11-38538

<151> 1999-02-17

<160> 16

<210> 1

<211> 47

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: multi-cloning site

<400> 1

gattcgtgca gatctcacac tgcagagatc caacagcatg gaagctt

47

<210> 2

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 2

acgccagggt tttcccagtc acgacg

26

<210> 3

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

2/4

<400> 3
atgattacgc caagcttcca tgctggctcc gatccgttt 39

<210> 4
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: adaptor

<400> 4
gatcgagatc tgcaaccaga gtcg 24

<210> 5
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: adaptor

<400> 5
cgactctggt tgcagatctc 20

<210> 6
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 6
aacttcgact gggccgcag atctcgatc 29

<210> 7
<211> 39
<212> DNA
<213> Mus musculus

<400> 7
tgcattccat c 11

3/4

<210> 8
<211> 11
<212> DNA
<213> Mus musculus

<400> 8
cctggtggaa a 11

<210> 9
<211> 11
<212> DNA
<213> Mus musculus

<400> 9
tgctctccac c 11

<210> 10
<211> 11
<212> DNA
<213> Mus musculus
<400> 10
gggaagtacg c 11

<210> 11
<211> 11
<212> DNA
<213> Mus musculus

<400> 11
acctcgatg a 11

<210> 12
<211> 11
<212> DNA
<213> Mus musculus

<400> 12
ttccaggccc g 11

<210> 13
<211> 11
<212> DNA

<400> 13

11

<210> 14

<211> 11

<212> DNA

<213> Mus musculus

<400> 14

11

<210> 15

<211> 11

<212> DNA

<213> Mus musculus

<400> 15

11

<210> 16

<211> 11

<212> DNA

<213> Mus musculus

<400> 16

11

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic DNA

<400> 1

gattcgtgca gatctcacac tgcagagatc caacagcatg gaagctt

47

<210> 2

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic DNA

<400> 2

acgccagggt tttcccagtc acgacg

26

<210> 3

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic DNA

<400> 3

atgattacgc caagcttcca tgctggctcc gatccgttt

39

<210> 4

<223> Synthetic DNA

<210> 5

<212> DNA

<213> Artificial Sequence

<223> Synthetic DNA

<210> 6

<211> 29

<212> DNA

<213> Artificial Sequence

<223> Synthetic DNA

```
<400> 6
aacttcgact gcggccgcag atctcgatc
```


<210>	8
<211>	11
<212>	DNA
<213>	Mus musculus

<210>	9
<211>	11
<212>	DNA
<213>	Mus musculus

<210>	10
<211>	11
<212>	DNA
<213>	Mus musculus

<213> Mus musculus

<400> 14
tgcatgccct g

11

<210> 15

<211> 11

<212> DNA

<213> Mus musculus

```
<400> 15
cactacagca c
```

11

<210> 16

<211> 11

<212> DNA

<213> Mus musculus

<400> 16
ctgccaagtt c

11

<210> 17

<211> 48

<212> DNA

<213> Artificial Sequence

 $\langle 220 \rangle$

<223> Synthetic DNA

<400> 17
aagcttccat gctgttggat ctctgcagtg tgagatctgc acgaattc

48

atggaagctt

10

<210> 21

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic DNA

<400> 21

gtgtgagatc tgcacgaatt c

21

<210> 22

<211> 13

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic DNA

<400> 22

ttggatctct gca

13

<210> 23

<211> 14

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic DNA

<400> 23
aagcttccat gctg

14

<210> 24

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic DNA

<400> 24
cggagtttaa acggattgga gccagc

26

<210> 25

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic DNA

<400> 25
gctccaatcc gtttaaactc cgtttttttt tttttttttt tttttttttt tttttttttt

60

tt

62

<210> 26

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic DNA

<400> 26
cggagtttaa acggattgga gccagcatgg aagctt 36

<210> 27

<211> 76

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic DNA

<400> 27
aagcttccat gctggctcca atccgtttaa actccgtttt tttttttttt tttttttttt 60
tttttttttt tttttt 76

<210> 28

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic DNA

<220>

<221> polyA_signal

<222> (1)..(24)

<223>

```
<400> 28
aaaaaaaaaa aaaaaaaaaa aaaa
```

24

<210> 29

<211> 66

<212> DNA

<213> Artificial Sequence

 $\langle 220 \rangle$

<223> Synthetic DNA

<400> 29

aagcttccat gctggctcca atccgtttaa actccgtttt tttttttttt tttttttttt

60

tttttt

66

<210> 30

<211> 104

<212> DNA

<213> Artificial Sequence

 $\langle 220 \rangle$

<223> Synthetic DNA

 $\langle 220 \rangle$

```
<221> misc_feature
```

<222> (1) . . (48)

<223> n = a, c, g, or t

<400> 30

```

nnnnnnnnnnnnnn nnnnnnnnnnnnnnn nnnnnnnnnnnnnnn nnnnnnnnnnnnnnn nnnnnnnnnnaa aaaaaaaaaa

```

60

aaaaaaaaacg gagtttaaac ggattggagc cagcatggaa gctt

104

<210> 31
 <211> 104
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic DNA
 <220>
 <221> misc_feature
 <222> (57)..(104)
 <223> n = a, c, g, or t

<400> 31
 aagcttccat gctggctcca atccgtttaa actccgtttt tttttttttt ttttttnnnn 60
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnn 104

<210> 32
 <211> 96
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic DNA
 <220>
 <221> misc_feature
 <222> (16)..(45)
 <223> n = a, c, g, or t

```
<400> 32
gaattcgtgc agatcnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnaaaa aaaaaaaaaa 60
cggagttaa acggattgga gccagcatgg aagctt 96
```

<210> 33

<211> 96

<212> DNA

<213> Artificial Sequence

 $\langle 220 \rangle$

<223> Synthetic DNA

 $\langle 220 \rangle$

```
<221> misc_feature
```

<222> (52) .. (81)

<223> n = a, c, g, or t

```
<400> 33
aagcttccat gctggctcca atccgtttta actccgtttt tttttttttt tnnnnnnnnn 60
nnnnnnnnnn nnnnnnnnnn ngatctgcac gaattc 96
```

<210> 34

<211> 28

<212> DNA

<213> Artificial Sequence

 $\langle 220 \rangle$

<223> Synthetic DNA

<220>

<221> misc_feature

<222> (16)..(28)

<223> n = a, c, g, or t

<400> 34

gaattcgtgc agatcnnnnn nnnnnnnn

28

<210> 35

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic DNA

<220>

<221> misc_feature

<222> (1)..(17)

<223> n = a, c, g, or t

<400> 35

nnnnnnnnnn nnnnnnnaaa aaaaaaaaaa aacggagttt

40

<210> 36

<211> 28

<212> DNA

<213> Artificial Sequence

$\langle 220 \rangle$

<223> Synthetic DNA

<400> 36

aaacggattg gagccagcat ggaagctt

28

<210> 37

<211> 26

<212> DNA

<213> Artificial Sequence

 $\langle 220 \rangle$

<223> Synthetic DNA

 $\langle 220 \rangle$

```
<221> misc feature
```

 $\langle 222 \rangle \quad (1) \dots (11)$

<223> n = a, c, g, or t

<400> 37

nnnnnnnnnn ngatctgcac gaattc

26

<210> 38

<211> 42

<212> DNA

<213> Artificial Sequence

$\langle 220 \rangle$

<223> Synthetic DNA

 $\langle 220 \rangle$

<400> 40
gaattcgtgc agatcnnnnn nnnnnnaaac ggattggagc cagcatggaa gctt 54

<210> 41

<211> 54

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic DNA

<220>

<221> misc_feature

<222> (29)..(39)

<223> n = a, c, g, or t

<400> 41
aagcttccat gctggctcca atccgtttnn nnnnnnnnng atctgcacga attc 54

<210> 42

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic DNA

<220>

<221> misc_feature

<222> (5)..(15)

<223> n = a, c, g, or t

```
<400> 42
gatcnnnnnnn nnnnnnaaacg gatc
```

24

<210> 43

<211> 24

<212> DNA

<213> Artificial Sequence

 $\langle 220 \rangle$

<223> Synthetic DNA

 $\langle 220 \rangle$

```
<221>  misc_feature
```

<222> (10) .. (20)

<223> n = a, c, g, or t

```
<400> 43
gatccggttn nnnnnnnnnn gatc
```

24

<210> 44

<211> 20

<212> DNA

<213> Artificial Sequence

 $\langle 220 \rangle$

<223> Synthetic DNA

 $\langle 220 \rangle$

<221> misc_feature

<222> (5)..(15)

<223> n = a, c, g, or t

<400> 44
gatchnnnnnn nnnnnaaacg

20

<210> 45

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic DNA

<220>

<221> misc_feature

<222> (10)..(20)

<223> n = a, c, g, or t

<400> 45
gatccgtttn nnnnnnnnnn

20